Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AUTOZONE INCAZO · Entity 8831 | Director | January 01, 2018 | January 02, 2018 |
| Oncternal Therapeutics, Inc.GTXI · Entity 89585 | Director · 10% owner | January 02, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AUTOZONE INC
Report date January 01, 2018 · Filed January 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,930.2 |
Reported balance
After 2018-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-01-01 · Grant · Acquired 302.23 · Balance 71,930.2 F1: Granted in accordance with the Amended and Restated AutoZone, Inc. 2011 Equity Incentive Award Plan (the "Plan"). Pursuant to the AutoZone, Inc. 2018 Director Compensation Program (the "2018 Program"), directors may elect to be paid either (1) 100% of their annual retainer fees and any additional fees in the form of restricted stock units ("RSUs") or (2) $85,000 of their annual retainer fees and any additional fees in the form of cash, with the remaining portion of the annual retainer fee ($130,000) paid in the form of restricted stock units. All fees taken in the form of RSUs are paid annually and any portion of the fees to be paid in cash are paid on a quarterly basis. F2: Restricted stock units (fully vested on the date of grant) issued to the reporting person in accordance with the Plan and the 2018 Program in lieu of the annual retainer fees in an aggregate amount equal to $215,000. The number of shares of the issuer's common stock underlying the restricted stock unit award is equal to the reporting person's aggregate annual retainer fees, divided by the closing market price of a share of the issuer's common stock on December 29, 2017. F4: The price per share is equal to the closing market price of a share of the issuer's common stock on December 29, 2017. F3: The shares will be delivered to the reporting person upon the earlier of (a) the date on which the reporting person ceases to be a director for any reason, provided that such reporting person incurs a "separation from service" from the issuer (within the meaning of Section 409A of the Internal Revenue Code and the related Treasury Regulations) (the "Termination Date") or (b) the fifth anniversary of the grant date, in which event the reporting person will have an opportunity to re-defer the delivery of the shares up to one year prior to the fifth anniversary; unless the reporting person has irrevocably elected in writing by December 31, 2017, to defer the delivery of such shares until the Termination Date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,000 |
Reported balance
Holding disclosure · report date 2018-01-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Granted in accordance with the Amended and Restated AutoZone, Inc. 2011 Equity Incentive Award Plan (the "Plan"). Pursuant to the AutoZone, Inc. 2018 Director Compensation Program (the "2018 Program"), directors may elect to be paid either (1) 100% of their annual retainer fees and any additional fees in the form of restricted stock units ("RSUs") or (2) $85,000 of their annual retainer fees and any additional fees in the form of cash, with the remaining portion of the annual retainer fee ($130,000) paid in the form of restricted stock units. All fees taken in the form of RSUs are paid annually and any portion of the fees to be paid in cash are paid on a quarterly basis.
F2: Restricted stock units (fully vested on the date of grant) issued to the reporting person in accordance with the Plan and the 2018 Program in lieu of the annual retainer fees in an aggregate amount equal to $215,000. The number of shares of the issuer's common stock underlying the restricted stock unit award is equal to the reporting person's aggregate annual retainer fees, divided by the closing market price of a share of the issuer's common stock on December 29, 2017.
F3: The shares will be delivered to the reporting person upon the earlier of (a) the date on which the reporting person ceases to be a director for any reason, provided that such reporting person incurs a "separation from service" from the issuer (within the meaning of Section 409A of the Internal Revenue Code and the related Treasury Regulations) (the "Termination Date") or (b) the fifth anniversary of the grant date, in which event the reporting person will have an opportunity to re-defer the delivery of the shares up to one year prior to the fifth anniversary; unless the reporting person has irrevocably elected in writing by December 31, 2017, to defer the delivery of such shares until the Termination Date.
F4: The price per share is equal to the closing market price of a share of the issuer's common stock on December 29, 2017.
Oncternal Therapeutics, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,207,367.974 |
Reported balance
After 2019-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 18,168.605 · Balance 4,207,367.974 F1: Includes annuity distributions of 500,000 shares from the 2017-7 Grantor Retained Annuity Trust, 500,000 shares from the 2017-8 Grantor Retained Annuity Trust, 500,000 shares from the 2017-9 Grantor Retained Annuity Trust, 250,000 shares from the 2017-10 Grantor Retained Annuity Trust, 250,000 from the 2017-11 Grantor Retained Annuity Trust and 250,000 shares from the 2017-12 Grantor Retained Annuity Trust to the reporting person on November 9, 2018 and represents a change in form of beneficial ownership. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 21,646 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21,646 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-1 GRAT | 457,337 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 457,337 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-2 GRAT | 457,337 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 457,337 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-3 GRAT | 457,337 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 457,337 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-4 GRAT | 228,668 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 228,668 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-5 GRAT | 228,668 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 228,668 |
| Common StockSEC Table I · non-derivative | IndirectBy 2017-6 GRAT | 228,668 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 228,668 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 50,889 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 50,889 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 50,889 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 50,889 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 50,889 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 50,889 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,378 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 20,378 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 11,435 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 11,435 |
| Common StockSEC Table I · non-derivative | IndirectBy Pittco Associates III, L.P. | 14,535 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 14,535 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in his report shall not be deemed an admission of beneficial ownership of the reported shares for the purpose of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Pittco Investments, L.P. | 391,571 |
Reported balance
Holding disclosure · report date 2019-01-02 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 391,571 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in his report shall not be deemed an admission of beneficial ownership of the reported shares for the purpose of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes annuity distributions of 500,000 shares from the 2017-7 Grantor Retained Annuity Trust, 500,000 shares from the 2017-8 Grantor Retained Annuity Trust, 500,000 shares from the 2017-9 Grantor Retained Annuity Trust, 250,000 shares from the 2017-10 Grantor Retained Annuity Trust, 250,000 from the 2017-11 Grantor Retained Annuity Trust and 250,000 shares from the 2017-12 Grantor Retained Annuity Trust to the reporting person on November 9, 2018 and represents a change in form of beneficial ownership.
F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in his report shall not be deemed an admission of beneficial ownership of the reported shares for the purpose of Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 3, 2019 16:27 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 18,168.605 | $0.86 | $15,625.00 |
DisclosureSEC source: 0001179110-19-000216 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,207,367.974 F1 · balance_after: Includes annuity distributions of 500,000 shares from the 2017-7 Grantor Retained Annuity Trust, 500,000 shares from the 2017-8 Grantor Retained Annuity Trust, 500,000 shares from the 2017-9 Grantor Retained Annuity Trust, 250,000 shares from the 2017-10 Grantor Retained Annuity Trust, 250,000 from the 2017-11 Grantor Retained Annuity Trust and 250,000 shares from the 2017-12 Grantor Retained Annuity Trust to the reporting person on November 9, 2018 and represents a change in form of beneficial ownership. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 17:01 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 10,416.666 | $1.50 | $15,625.00 |
DisclosureSEC source: 0001179110-18-011926 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,199.369 Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 11:06 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,010.02 | $15.47 | $15,625.01 |
DisclosureSEC source: 0001179110-18-009273 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,928,782.703 Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:47 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 894.391 | $17.47 | $15,625.01 |
DisclosureSEC source: 0001179110-18-005242 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927,772.683 F1 · balance_after: Includes annuity distributions of 42,663 shares from the 2017-1 Grantor Retained Annuity Trust, 42,663 shares from the 2017-2 Grantor Retained Annuity Trust, 42,663 shares from the 2017-3 Grantor Retained Annuity Trust, 21,332 shares from the 2017-4 Grantor Retained Annuity Trust, 21,332 from the 2017-5 Grantor Retained Annuity Trust and 21,332 shares from the 2017-6 Grantor Retained Annuity Trust to the reporting person on February 28, 2018 and represents a change in form of beneficial ownership. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 12:39 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,363.438 | $11.46 | $15,625.00 |
DisclosureSEC source: 0001179110-18-000481 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,893.292 F1 · balance_after: Excludes 2,250,000 shares previously owned directly by the reporting person which were contributed to the 2017-7, 2017-8, 2017-9, 2017-10, 2017-11 and 2017-12 Grantor Retained Annuity Trusts on November 9, 2017 and represents a change in form of beneficial ownership. Read SEC document |
| January 01, 2018 Filed Jan 2, 2018 21:18 UTC | AUTOZONE INC AZO · Entity 8831 | GrantCommon Stock | 302.23 | $711.37 | $214,997.36 |
DisclosureSEC source: 0001225208-18-000084 · doc4.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,930.2 F1 · security: Granted in accordance with the Amended and Restated AutoZone, Inc. 2011 Equity Incentive Award Plan (the "Plan"). Pursuant to the AutoZone, Inc. 2018 Director Compensation Program (the "2018 Program"), directors may elect to be paid either (1) 100% of their annual retainer fees and any additional fees in the form of restricted stock units ("RSUs") or (2) $85,000 of their annual retainer fees and any additional fees in the form of cash, with the remaining portion of the annual retainer fee ($130,000) paid in the form of restricted stock units. All fees taken in the form of RSUs are paid annually and any portion of the fees to be paid in cash are paid on a quarterly basis. F2 · shares: Restricted stock units (fully vested on the date of grant) issued to the reporting person in accordance with the Plan and the 2018 Program in lieu of the annual retainer fees in an aggregate amount equal to $215,000. The number of shares of the issuer's common stock underlying the restricted stock unit award is equal to the reporting person's aggregate annual retainer fees, divided by the closing market price of a share of the issuer's common stock on December 29, 2017. F4 · price: The price per share is equal to the closing market price of a share of the issuer's common stock on December 29, 2017. F3 · acquired: The shares will be delivered to the reporting person upon the earlier of (a) the date on which the reporting person ceases to be a director for any reason, provided that such reporting person incurs a "separation from service" from the issuer (within the meaning of Section 409A of the Internal Revenue Code and the related Treasury Regulations) (the "Termination Date") or (b) the fifth anniversary of the grant date, in which event the reporting person will have an opportunity to re-defer the delivery of the shares up to one year prior to the fifth anniversary; unless the reporting person has irrevocably elected in writing by December 31, 2017, to defer the delivery of such shares until the Termination Date. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 21:14 UTC | AUTOZONE INC AZO · Entity 8831 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $119.15 | $0.00 |
DisclosureSEC source: 0001225208-17-018670 · doc4.xml · derivative · entry 3 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2018-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted in accordance with the AutoZone, Inc. 2003 Director Stock Option Plan. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 21:14 UTC | AUTOZONE INC AZO · Entity 8831 | Exercise / conversionCommon Stock | 3,000 | $119.15 | $357,435.00 |
DisclosureSEC source: 0001225208-17-018670 · doc4.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,627.97 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:05 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,967.884 | $7.94 | $15,625.00 |
DisclosureSEC source: 0001179110-17-013086 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,983,529.854 Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:14 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock Warrants (right to buy) · Derivative | 678,349 | Not disclosed Strike: $9.02 | Not disclosed |
DisclosureSEC source: 0001179110-17-012838 · edgar.xml · derivative · entry 16 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,349 Underlying: Common Stock · 678,349 shares Expires 2022-09-29 F1 · price: The reported securities are included within 1,130,582 immediately separable Units purchased by the reporting person for $8.845 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase 0.60 of a share of Common Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:14 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,130,582 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-012838 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981,561.97 F1 · price: The reported securities are included within 1,130,582 immediately separable Units purchased by the reporting person for $8.845 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase 0.60 of a share of Common Stock. F2 · balance_after: Includes annuity distributions 20,043 shares from the 2014-4 Grantor Retained Annuity Trust, 1,336 shares from the 2014-5 Grantor Retained Annuity Trust and 1,336 shares from the 2014-6 Grantor Retained Annuity Trust to the reporting person on August 19, 2017 and represents a change in form of beneficial ownership. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 17:51 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 2,970.533 | $5.26 | $15,625.00 |
DisclosureSEC source: 0001179110-17-010009 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,828,264.97 F1 · balance_after: Includes annuity distributions 195,654 shares from the 2015-1 Grantor Retained Annuity Trust, 97,827 shares from the 2015-2 Grantor Retained Annuity Trust, 65,218 shares from the 2015-3 Grantor Retained Annuity Trust,195,654 shares from the 2015-4 Grantor Retained Annuity Trust and 195,654 shares from the 2015-5 Grantor Retained Annuity Trust to the reporting person on May 13, 2017 and represents a change in form of beneficial ownership. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:59 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 3,188.775 | $4.90 | $15,625.00 |
DisclosureSEC source: 0001179110-17-005782 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,075,287.437 F1 · balance_after: Excludes 2,250,000 shares previously owned directly by the reporting person which were contributed to the 2017-1, 2017-2, 2017-3, 2017-4, 2017-5 and 2017-6 Grantor Retained Annuity Trusts on February 28, 2017 and represents a change in form of beneficial ownership. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:03 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 2,999.041 | $5.21 | $15,625.00 |
DisclosureSEC source: 0001179110-17-000264 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,322,098.662 F1 · balance_after: On December 5, 2016, the Issuer effected a one-for-ten reverse stock split of its Common Stock (the "Reverse Split"). The number of securities beneficially owned by the Reporting Person has been adjusted to reflect the Reverse Split. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 21:37 UTC | AUTOZONE INC AZO · Entity 8831 | GrantCommon Stock | 259.56 | $789.79 | $204,997.89 |
DisclosureSEC source: 0001225208-17-000099 · doc4.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,627.97 F1 · security: Granted in accordance with the Amended and Restated AutoZone, Inc. 2011 Equity Incentive Award Plan (the "Plan"). Pursuant to the AutoZone, Inc. 2016 Director Compensation Program (the "2016 Program"), directors may elect to be paid either (1) 100% of their annual retainer fees and any additional fees in the form of restricted stock units ("RSUs") or (2) $80,000 of their annual retainer fees and any additional fees in the form of cash, with the remaining portion of the annual retainer fee ($125,000) paid in the form of restricted stock units. All fees taken in the form of RSUs are paid annually and any portion of the fees to be paid in cash are paid on a quarterly basis. F2 · shares: Restricted stock units (fully vested on the date of grant) issued to the reporting person in accordance with the Plan and the 2016 Program in lieu of the annual retainer fees in an aggregate amount equal to $205,000. The number of shares of the issuer's common stock underlying the restricted stock unit award is equal to the reporting person's aggregate annual retainer fees, divided by the closing market price of a share of the issuer's common stock on December 30, 2016. F4 · price: The price per share is equal to the closing market price of a share of the issuer's common stock on December 30, 2016. F3 · acquired: The shares will be delivered to the reporting person upon the earlier of (a) the date on which the reporting person ceases to be a director for any reason, provided that such reporting person incurs a "separation from service" from the issuer (within the meaning of Section 409A of the Internal Revenue Code and the related Treasury Regulations) (the "Termination Date") or (b) the fifth anniversary of the grant date, in which event the reporting person will have an opportunity to re-defer the delivery of the shares up to one year prior to the fifth anniversary; unless the reporting person has irrevocably elected in writing by December 31, 2016, to defer the delivery of such shares until the Termination Date. Read SEC document |
| October 27, 2016 Filed Oct 27, 2016 21:49 UTC | AUTOZONE INC AZO · Entity 8831 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $116.35 | $0.00 |
DisclosureSEC source: 0001225208-16-040794 · doc4.xml · derivative · entry 3 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2017-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted in accordance with the AutoZone, Inc. 2003 Director Stock Option Plan. Read SEC document |
| October 27, 2016 Filed Oct 27, 2016 21:49 UTC | AUTOZONE INC AZO · Entity 8831 | Exercise / conversionCommon Stock | 3,000 | $116.35 | $349,035.00 |
DisclosureSEC source: 0001225208-16-040794 · doc4.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,368.41 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2016 Filed Oct 17, 2016 16:17 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 7,716,049 | $0.81 | $6,249,999.69 |
DisclosureSEC source: 0001179110-16-030749 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,191,009.21 Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 17:02 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 20,559.21 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030309 · edgar.xml · nonDerivative · entry 1 HYDE JOSEPH R III · CIK 0000903352 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,474,960.24 F1 · balance_after: Includes annuity distributions of 1,853,096 shares from the 2014-4 Grantor Retained Annuity Trust, 123,540 shares from the 2014-5 Grantor Retained Annuity Trust and 123,540 shares from the 2014-6 Grantor Retained Annuity Trust to the reporting person on August 19, 2016 and represents a change in form of beneficial ownership. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.